Artera Secures Best in KLAS Win as AI Investments Push Patient Communications Past $100M CARR

New updates have been reported about Artera.

Artera has been named the No. 1 Best in KLAS vendor for Patient Communications for 2026, reinforcing its position as a key infrastructure player in digital health workflows. Based on feedback from more than 20 healthcare providers, the firm earned an overall score of 89.8 with straight A- grades across Culture, Loyalty, Operations, Product, Relationship, and Value, a signal to the market that health systems view Artera as a reliable, ROI-focused partner.

The award caps a year of notable financial and strategic milestones for Artera, including a $65 million growth investment aimed at accelerating deployment of its agentic AI platform and surpassing $100 million in Contracted Annual Recurring Revenue. The company now supports roughly 2 billion patient communications annually for over 1,000 healthcare organizations, positioning its platform as a critical component in reducing administrative cost and improving access across scheduling, intake, and billing.

A centerpiece of Artera’s strategy is its Virtual Agent portfolio, launched at its Heartbeat’24 customer conference and now deployed by hundreds of providers to address staffing constraints and patient access bottlenecks. Flows Agents manage over 42 million sessions annually and resolve about 94 percent of conversations without staff involvement, while AI Co-Pilots are live at more than 100 providers, cutting response times and summarizing conversations to reduce administrative load.

Management has also focused on shaping industry thinking on AI adoption, with CEO and Co-founder Guillaume de Zwirek recently featured in a healthsystemCIO special AI report and the launch of the “Decoding AI Agents for Healthcare” series to guide provider decision-making on security, interoperability, and model frameworks. Artera emphasizes an enterprise-grade security posture—HITRUST certified, SOC 2 Type 2, HIPAA compliant, and pursuing FedRAMP High—while stating it does not use PHI or PII to train models, which is increasingly pivotal for large health systems and federal customers.

The company’s growth profile is supported by a long-running awards track record, including repeated inclusion on Deloitte’s Technology Fast 500 and the Inc. 5000, as well as category wins from Medtech Breakthrough, Frost & Sullivan, and AVIA Marketplace in AI and patient engagement. Workplace accolades from Built In, Forbes, Newsweek, and Business Insider further strengthen Artera’s talent brand, which is strategically important as it scales AI, implementation, and customer success teams to meet rising demand.

For executives and investors, the combination of KLAS validation, fresh growth capital, and a scaled AI product suite indicates Artera is moving from point-solution status toward being a core communications and automation layer for healthcare providers. The forward-looking statements in the release highlight that product roadmap and financial outcomes remain exposed to typical execution and market risks, but current adoption metrics and third-party recognition suggest meaningful runway for continued CARR expansion and deeper penetration of AI agents across Artera’s installed base.